| Literature DB >> 35411179 |
Jun Deng1, Shifa Zhou1, Zhiwen Wang1, Genbo Huang1, Jingjun Zeng1, Xiujiang Li1.
Abstract
Background: Limited evidence and contradictory results have been reported regarding the impact of tumor site on lymph node metastasis (LNM) and prognosis in T1 stage adenocarcinoma (AC). We aimed to compare two anatomic locations in terms of LNM and prognosis using a comprehensive statistical analysis of a large population.Entities:
Keywords: SEER; anatomic location; colorectal adenocarcinoma; lymph node metastasis; survival
Year: 2022 PMID: 35411179 PMCID: PMC8994659 DOI: 10.2147/IJGM.S354120
Source DB: PubMed Journal: Int J Gen Med ISSN: 1178-7074
Figure 1Flow chart of patient information extraction from the SEER database.
Basic Information of Patients with Colorectal Adenocarcinoma in T1 Stage from 2010 Through 2015 in SEER Database
| Total | Colonic Adenocarcinoma | Rectum Adenocarcinoma | P value | |
|---|---|---|---|---|
| Total | 12,404 | 9655 | 2749 | |
| Gender | ||||
| Male | 6432 (51.85%) | 4887 (50.62%) | 1545 (56.2%) | |
| Female | 5972 (48.15%) | 4768 (49.38%) | 1204 (43.8%) | |
| Race | ||||
| White | 9842 (79.35%) | 7622 (78.94%) | 2220 (80.76%) | |
| Black | 1428(11.51%) | 1196 (12.39%) | 232 (8.44%) | |
| Another race | 1134 (9.14%) | 837 (8.67%) | 297(10.80%) | |
| Age | ||||
| ≤50 | 995 (8.02%) | 619 (6.41%) | 376 (13.68%) | |
| >50 | 11,409 (91.98%) | 9036 (93.59%) | 2373 (86.32%) | |
| Grade | ||||
| Well differentiated | 2276(18.35%) | 1924 (19.93%) | 352(12.80%) | |
| Moderately | 9152 (73.78%) | 6969 (72.18%) | 2183 (79.41%) | |
| Poorly differentiated | 832 (6.71%) | 649 (6.72%) | 183 (6.66%) | |
| Undifferentiated | 144 (1.16%) | 113 (1.17%) | 31 (1.13%) | |
| N stage | ||||
| No | 10,790 (86.99%) | 8529 (88.34%) | 2261 (82.25%) | |
| Yes | 1614 (13.01%) | 1126 (11.66%) | 488 (17.75%) | |
| M stage | ||||
| No | 12,269 (98.91%) | 9566 (99.08%) | 2703 (98.33%) | |
| Yes | 135 (1.09%) | 89 (0.92%) | 46 (1.67%) | |
| Tumor size | ||||
| ≤3cm | 10,526 (84.86%) | 8326 (86.24%) | 2200 (80.03%) | |
| >3cm | 1878 (15.14%) | 1329 (13.76%) | 549 (19.97%) | |
| Examined LNs | ||||
| <12 | 3884 (31.31%) | 2903 (30.07%) | 981 (35.69%) | |
| ≥12 | 8520 (68.69%) | 6752 (69.93%) | 1768 (64.31%) | |
| Liver metastasis | ||||
| No | 12,303 (99.19%) | 9588 (99.31%) | 2715 (98.76%) | |
| Yes | 101 (0.81%) | 67 (0.69%) | 34 (1.24%) | |
| Lung metastasis | 0.479 | |||
| No | 12,383 (99.83%) | 9640 (99.84%) | 2743 (99.78%) | |
| Yes | 21 (0.17%) | 15 (0.16%) | 6 (0.22%) |
Note: Italic values indicate statistical significance when P<0.05.
Figure 2Flow chart of patient information extraction from the First Affiliated Hospital of Nanchang University.
Basic Information of Patients with Colorectal Cancer in T1 Stage from Our Hospital Diagnosed from 2010 Through 2018
| Total | Colonic Adenocarcinoma | Rectal Adenocarcinoma | P value | |
|---|---|---|---|---|
| Total | 516 | 184 | 332 | |
| Gender | 0.697 | |||
| Male | 297 (57.56%) | 108 (58.70%) | 189 (56.93%) | |
| Female | 219 (42.44%) | 76 (41.30%) | 143 (43.07%) | |
| T stage | ||||
| T1a | 162 (31.40%) | 43 (23.37%) | 119 (35.84%) | |
| T1b | 354 (68.60%) | 141 (76.63%) | 213 (64.16%) | |
| Tumor type | 0.462 | |||
| Uplift type | 312 (60.47%) | 105 (57.07%) | 207 (62.35%) | |
| Ulcerative type | 112 (21.71%) | 42 (22.83%) | 70 (21.08%) | |
| Invasive type | 92 (17.83%) | 37 (20.11%) | 55 (16.57%) | |
| Age | 0.254 | |||
| ≤50 | 128 (24.81%) | 51 (27.72%) | 77 (23.19%) | |
| >50 | 388 (75.19%) | 133 (72.28%) | 255 (76.81%) | |
| Pathological grade | ||||
| Well differentiated | 110 (21.32%) | 52 (28.26%) | 58 (17.47%) | |
| Moderately | 363 (70.35%) | 112 (60.87%) | 251 (75.60%) | |
| Poorly differentiated | 43 (8.33%) | 20 (10.87%) | 23 (6.93%) | |
| N stage | ||||
| No | 465 (90.12%) | 173 (94.02%) | 292 (87.95%) | |
| Yes | 51 (9.88%) | 11 (5.98%) | 40 (12.05%) | |
| Lymphatic invasion | 0.502 | |||
| No | 489 (94.77%) | 176 (95.65%) | 313 (94.28%) | |
| Yes | 27 (5.23%) | 8 (4.35%) | 19 (5.72%) | |
| M stage | 0.905 | |||
| No | 510 (98.84%) | 182 (98.91%) | 328 (98.80%) | |
| Yes | 6 (1.16%) | 2 (1.09%) | 4 (1.20%) | |
| Tumor size | 0.276 | |||
| ≤3cm | 349 (67.64%) | 130 (70.65%) | 219 (65.96%) | |
| >3cm | 167 (32.36%) | 54 (29.35%) | 113 (34.04%) | |
| Examined LNs | ||||
| <12 | 359 (69.57%) | 113 (61.41%) | 246 (74.10%) | |
| ≥12 | 157 (30.43%) | 71 (38.59%) | 86 (25.90%) | |
| Chemotherapy | 0.696 | |||
| No | 480 (93.02%) | 170 (92.39%) | 310 (93.37%) | |
| Yes | 36 (6.98%) | 14 (7.61%) | 22 (6.63%) | |
| Surgery methods | ||||
| Laparoscopy | 342 (66.28%) | 136 (73.91%) | 206 (62.05%) | |
| Robot surgery | 71 (13.76%) | 21 (11.41%) | 50 (15.06%) | |
| Normal surgery | 103 (19.96%) | 27 (14.67%) | 76 (22.89%) | |
| Radiotherapy | 0.165 | |||
| No | 504 (97.67%) | 182 (98.91%) | 322 (96.99%) | |
| Yes | 12 (2.33%) | 2 (1.09%) | 10 (3.01%) | |
| Smoking | 0.859 | |||
| No | 379 (73.45%) | 136 (73.91%) | 243 (73.19%) | |
| Yes | 137 (26.55%) | 48 (26.09%) | 89 (26.81%) | |
| Drinking | 0.275 | |||
| No | 410 (79.46%) | 151 (82.07%) | 259 (78.01%) | |
| Yes | 106 (20.54%) | 33 (17.93%) | 73 (21.99%) | |
| Family history | 0.865 | |||
| No | 504 (97.67%) | 180 (97.83%) | 324 (97.59%) | |
| Yes | 12 (2.33%) | 4 (2.17%) | 8 (2.41%) |
Note: Italic values indicate statistical significance when P<0.05.
Figure 3Comparison of OS (A) and CSS (B) between T1 stage colonic and rectal AC.
Figure 4Standardized mean difference (SMD) across covariates before and after PSM as well as the association between tumor site and survival.
Figure 5Comparison of OS (A) and CSS (B) between T1 stage colonic and rectal AC after PSM using the SEER data.
Figure 6K-M survival curve analysis comparing T1 stage colonic and rectal AC using the data from our hospital.
Univariate and Multivariate Cox Regression Model for Exploring the Potential Risk Factors for OS in Patients from SEER Database
| Variables | Univariate Analysis | P value | Multivariate Analysis | P value |
|---|---|---|---|---|
| Age | ||||
| ≤50 | Reference | – | Reference | – |
| >50 | 3.459(2.516–4.754) | 3.485(2.532–4.796) | ||
| Gender | ||||
| Male | Reference | – | Reference | – |
| Female | 0.891(0.804–0.987) | 0.885(0.798–0.981) | ||
| Race | ||||
| White | Reference | Reference | – | |
| Black | 1.263(1.088–1.466) | 1.255(1.080–1.458) | ||
| Another race | 0.706(0.570–874) | 0.699(0.565–0.866) | ||
| Primary Site | ||||
| Colon | Reference | – | Reference | |
| Rectum | 0.825(0.725–0.939) | 0.826(0.724–0.943) | ||
| Grade | ||||
| Well differentiated | Reference | – | Reference | – |
| Moderately | 0.978(0.855–1.118) | 0.741 | 1.025(0.896–1.173) | 0.720 |
| Poorly differentiated | 1.343(1.087–1.658) | 1.426(1.154–1.763) | ||
| Undifferentiated | 1.843(1.241–2.738) | 1.997(1.344–2.968) | ||
| Tumor size | ||||
| ≤3cm | Reference | – | Reference | – |
| >3cm | 1.377(1.210–1.568) | 1.360(1.191–1.554) | ||
| Examined LNs | ||||
| <12 | Reference | – | Reference | – |
| ≥12 | 0.825(0.742–0.917) | 0.811(0.729–0.903) | ||
| LNM | ||||
| No | Reference | – | Reference | – |
| Yes | 4.861(3.576–6.609) | 4.732(3.368–6.648) | ||
| Metastasis | ||||
| No | Reference | – | Reference | – |
| Yes | 5.112(2.744–9.521) | 5.84(2.197–9.334) |
Note: Italic values indicate statistical significance when P<0.05.